InnoCare's next-generation TRKi Zurletrectinib Receives Priority Review for the Treatment of Pediatric Patients with Solid Tumors in China
MWN-AI** Summary
InnoCare Pharma (HKEX: 09969), a prominent biopharmaceutical company specializing in cancer and autoimmune disease therapies, has recently announced that its next-generation TRK inhibitor, zurletrectinib (ICP-723), has received priority review status from the China National Medical Products Administration (NMPA) for treating pediatric patients aged 2 to 12 with solid tumors featuring NTRK gene fusions. This classification is part of the CDE's efforts to expedite drug approval processes for significant therapeutic advancements. Additionally, zurletrectinib has been accepted into the CDE’s “SPARK Program,” aimed at fostering the development of pediatric anti-tumor medications.
Previously, in December 2025, zurletrectinib had already been approved for use in adult and adolescent patients (aged 12 and older) with NTRK fusion-positive solid tumors in China. Clinical trials indicate a promising therapeutic profile for zurletrectinib, showcasing an impressive objective response rate (ORR) of 89.1% and a disease control rate (DCR) of 96.4%. The long-term outcomes were equally encouraging, with 24-month progression-free survival (PFS) and overall survival (OS) rates recorded at 77.4% and 90.8%, respectively.
The drug's pediatric clinical data, presented at the Congress of International Society of Pediatric Oncology (SIOP) in October 2025, highlighted zurletrectinib's strong safety profile and efficacy in treating pediatric patients with NTRK/ROS1-altered solid tumors. With an estimated 6,500 new cases of NTRK fusion-positive solid tumors diagnosed annually in China, zurletrectinib addresses a critical unmet need, particularly for rare tumors where NTRK gene fusions are often prevalent. InnoCare continues to push the boundaries of cancer treatment through its innovative research and development initiatives, aiming for impactful solutions globally.
MWN-AI** Analysis
InnoCare Pharma (HKEX: 09969) has made significant strides in the biotechnology sector with its next-generation TRK inhibitor, zurletrectinib (ICP-723). Its recent designation of priority review by the Center for Drug Evaluation (CDE) in China for pediatric patients with solid tumors harboring NTRK gene fusions indicates a robust growth trajectory. Given the promising clinical trial results—showcasing an objective response rate of 89.1% and an impressive overall survival rate of 90.8%—investors should consider the potential upside of InnoCare’s stock.
The active inclusion of zurletrectinib in the CDE's “SPARK Program” bolsters its market positioning in the pediatric oncology space, a segment with limited effective treatment options. With approximately 6,500 new cases of NTRK fusion-positive solid tumors diagnosed annually in China, the demand for effective therapies is pressing. As regulatory timelines shorten, InnoCare stands poised to capture market share rapidly.
Investors should be aware of the broader trends in oncology, especially the shift towards precision medicine, where targeted therapies like zurletrectinib are becoming the standard of care. As healthcare systems globally increasingly recognize the importance of personalized treatment options, InnoCare's innovative portfolio may elevate its standing among biopharmaceutical leaders.
However, it's crucial to approach with caution. While the approval process is accelerating, potential risks and uncertainties surrounding clinical trials, market adoption rates, pricing strategies, and competition from other biotech firms exist.
In summary, InnoCare's pipeline and strategic initiatives position it favorably within the oncology domain, particularly concerning pediatric treatments. Investors should monitor forthcoming clinical data, market entry strategies, and regulatory decisions to make informed decisions. Emphasizing a balanced approach can yield fruitful opportunities in this evolving market.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
BEIJING, March 01, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969), a leading biopharmaceutical company for the treatment of cancer and autoimmune diseases, announced today that its next generation TRK inhibitor zurletrectinib (ICP-723) has been granted priority review by the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA), for the treatment of pediatric patients (aged 2 to 12) with solid tumors harboring NTRK gene fusions. Priority review is one of the key policies introduced by the CDE to accelerate drug approval.
Zurletrectinib has also been included in the “SPARK Program” by the CDE, a pilot initiative to encourage the development of pediatric anti-tumor drugs.
In December 2025, zurletrectinib received approval for the treatment of adult and adolescent patients (aged 12 years and older) with solid tumors harboring NTRK gene fusions in China. In the registrational clinical trial for patients with NTRK fusion-positive solid tumors, zurletrectinib demonstrated outstanding efficacy and a favorable safety profile. The study results showed an objective response rate (ORR) of 89.1%, a disease control rate (DCR) of 96.4%, and 24-month progression-free survival (PFS) and overall survival (OS) rates of 77.4% and 90.8% respectively.
In October 2025, the data from the Phase I/II clinical trial of zurletrectinib for the treatment of pediatric and adolescent patients with advanced solid tumors were released at the Congress of International Society of Pediatric Oncology (SIOP) 2025 as an oral presentation. Zurletrectinib demonstrated a well-tolerated safety profile and promising antitumor activity in pediatric/adolescent patients with NTRK/ROS1-altered solid tumors. The results highlight zurletrectinib's strong potential as a next-generation therapy for NTRK/ROS1-driven malignancies, with the ability to overcome resistance to first-generation TRK inhibitors.
NTRK fusion genes occur in various types of adult and pediatric tumors. In some rare tumors, such as salivary gland carcinoma, secretory breast cancer, and infantile fibrosarcoma, the incidence of NTRK gene fusion exceeds 90%1. It is estimated that there are about 6,500 new cases of NTRK fusion-positive solid tumors diagnosed in China each year. There are significant unmet clinical needs in this area due to the lack of effective treatment options.
About InnoCare
InnoCare is a commercial stage biopharmaceutical company committed to discovering, developing, and commercializing first-in-class and/or best-in-class drugs for the treatment of cancers and autoimmune diseases with unmet medical needs in China and worldwide. InnoCare has branches in Beijing, Nanjing, Shanghai, Guangzhou, Hong Kong, and the United States.
InnoCare Forward-looking Statements
This report contains the disclosure of some forward-looking statements. Except for statements of facts, all other statements can be regarded as forward-looking statements, that is, about our or our management's intentions, plans, beliefs, or expectations that will or may occur in the future. Such statements are assumptions and estimates made by our management based on its experience and knowledge of historical trends, current conditions, expected future development and other related factors. This forward-looking statement does not guarantee future performance, and actual results, development and business decisions may not match the expectations of the forward-looking statement. Our forward-looking statements are also subject to a large number of risks and uncertainties, which may affect our short-term and long-term performance.
| Contact | |
| Media | Investors |
| Chunhua Lu 86-10-66609879 chunhua.lu@innocarepharma.com | 86-10-66609999 ir@innocarepharma.com |
1 Cocco, E., Scaltriti, M., and Drilon, A. (2018). NTRK fusion-positive cancers and TRK inhibitor therapy. Nature Reviews Clinical Oncology 15, 731-747.
FAQ**
How does InnoCare Pharma INCPF plan to leverage the priority review status granted to zurletrectinib in terms of its market strategy for pediatric patients with NTRK fusion-positive tumors?
What are the implications of zurletrectinib's inclusion in the CDE's SPARK Program for InnoCare Pharma INCPF's long-term research and development investments in pediatric oncology?
Given the reported 89.1% objective response rate for zurletrectinib, how does InnoCare Pharma INCPF intend to differentiate its product within an increasingly competitive TRK inhibitor market?
What strategies does InnoCare Pharma INCPF have in place to address the significant unmet clinical needs for pediatric patients with NTRK fusion-positive tumors following zurletrectinib's approval?
**MWN-AI FAQ is based on asking OpenAI questions about InnoCare Pharma (OTC: INCPF).
NASDAQ: INCPF
INCPF Trading
0.0% G/L:
$1.55 Last:
1,000 Volume:
$1.55 Open:
